Cargando…
Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders
The clinical failure rate for disease-modifying treatments (DMTs) that slow or stop disease progression has been nearly 100% for the major neurodegenerative disorders (NDDs), with many compounds failing in expensive and time-consuming phase 2 and 3 trials for lack of efficacy. Here, we critically re...
Autores principales: | Vissers, Maurits F. J. M., Heuberger, Jules A. A. C., Groeneveld, Geert Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915613/ https://www.ncbi.nlm.nih.gov/pubmed/33562713 http://dx.doi.org/10.3390/ijms22041615 |
Ejemplares similares
-
A leucine‐rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls
por: Vissers, Maurits F. J. M., et al.
Publicado: (2023) -
Proof of concept demonstration of optimal composite MRI endpoints for clinical trials
por: Edland, Steven D., et al.
Publicado: (2016) -
Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo‐controlled, double‐blind phase I/Ib studies in healthy subjects and patients
por: Vissers, Maurits F. J. M., et al.
Publicado: (2022) -
Pharmacological and Nutraceutical Activation of Rejuvenation, Geroprotection and Cytoprotection: Proofs of Concept
por: Lizard, Gérard, et al.
Publicado: (2022) -
Proof-of-concept for characterization of neurodegenerative disorders utilizing two non-REM sleep biomarkers
por: Levendowski, Daniel J., et al.
Publicado: (2023)